Skip to main content

Together we are beating cancer

Donate now

Tim Gunn

Tim is a senior digital news officer at Cancer Research UK. He started writing about science after studying English literature at Cambridge and magazine journalism at City, University of London. Before joining the digital news team in August 2022, he was a journalist and medical magazine editor.
Tim Gunn
Showing 12 out of 40 results
An unrecognisable young girl receiving a vaccination.

The HPV vaccine is preventing the highest number of cervical cancer cases in the most deprived groups in England. The HPV vaccine is preventing the highest number of cervical cancer cases in the most deprived groups in England.

by Tim Gunn | News | 16 May 2024

16 May 2024

Sample bottles in a lab

Proteins in people's blood could be used to find and even one day prevent cancers, according to the team behind two of our latest studies. Proteins in people's blood could be used to find and even one day prevent cancers, according to the team behind two of our latest studies.

by Tim Gunn | News | 15 May 2024

15 May 2024

Issy, Jake and Joram, who shared their stories with us for Teenage and Young Adult Cancer Awareness Month.

April is Teenage and Young Adult Cancer Awareness Month. Three teenagers who were diagnosed with cancer share their experiences and advice. April is Teenage and Young Adult Cancer Awareness Month. Three teenagers who were diagnosed with cancer share their experiences and advice.

by Tom Bourton, Tim Gunn | Personal stories | 2 April 2024

2 April 2024

A Cancer Grand Challenges-branded graphic reading 'Announcing five new global Cancer Grand Challenges teams'
  • Science & Technology
  • Health & Medicine
  • Charity News

Cancer Grand Challenges gives a record £100m to five cancer research teams

Cancer Grand Challenges has awarded five research teams up to £20m each in its largest ever funding round. They will now take on four of the biggest questions in cancer.   Cancer Grand Challenges has awarded five research teams up to £20m each in its largest ever funding round. They will now take on four of the biggest questions in cancer.  

by Tim Gunn | News, Analysis | 6 March 2024

6 March 2024

Cells with nuclei in blue and mitochondria (energy factories) in green.

Our researchers have found mutations that make cancers much more likely to respond to immunotherapy. It's a chance to make breakthrough treatments work for many more people. Our researchers have found mutations that make cancers much more likely to respond to immunotherapy. It's a chance to make breakthrough treatments work for many more people.

by Tim Gunn | Analysis | 31 January 2024

31 January 2024

An image of a capsule sponge, a test for Barrett's oesophagus and oesophageal cancer

Our BEST4 trial will show if a capsule sponge test can be used to monitor people at high risk of oesophageal cancer. It could give the NHS a quick and simple new screening test for oesophageal cancer and save thousands of lives every year.  Our BEST4 trial will show if a capsule sponge test can be used to monitor people at high risk of oesophageal cancer. It could give the NHS a quick and simple new screening test for oesophageal cancer and save thousands of lives every year. 

by Tim Gunn | Analysis | 11 January 2024

11 January 2024

A Cancer Research UK-funded researcher in the lab.

We helped fund a trial into neuroblastoma treatment that has improved how doctors treat the disease when other options aren't working. It's an important step forward in treating these relapsed and refractory tumours, which have some of the lowest survival rates for any childhood cancer.   We helped fund a trial into neuroblastoma treatment that has improved how doctors treat the disease when other options aren't working. It's an important step forward in treating these relapsed and refractory tumours, which have some of the lowest survival rates for any childhood cancer.  

by Tim Gunn | News | 10 January 2024

10 January 2024

The International Agency for Research on Cancer's (IARC's) website, seen on a phone and a computer.

The International Agency for Research on Cancer has evaluated the risks of two types of forever chemical. Here's what the evidence tells us. The International Agency for Research on Cancer has evaluated the risks of two types of forever chemical. Here's what the evidence tells us.

by Tim Gunn, Sophie Brooks | News | 11 December 2023

11 December 2023